Infliximab is an anti‐tumor necrosis factor‐alpha monoclonal antibody that is highly effective for the treatment of psoriatic disease. During maintenance treatment, some patients may experience a disease relapse, and, in such circumstances, dose intensification is frequently used to regain efficacy. We report our cumulative experience on the use of infliximab re‐induction in patients whose psoriasis relapsed during long‐term maintenance treatment with infliximab. From September 2005 to January 2009, 22 patients required re‐induction because of a relapse of their psoriasis. Re‐induction was effective in restoring response in most patients and was well tolerated in all cases, without occurrence of serious or unexpected adverse events.